Annovis Bio (ANVS) EBT (2019 - 2026)
Annovis Bio (ANVS) posted EBT of -$18.1 million for Q1 2026, down 75.63% sequentially from -$10.3 million in Q4 2025, and down 196.4% YoY from $18.8 million in Q1 2025.
Annovis Bio (ANVS) EBT (2019 - 2026) Analysis & Trends
Annovis Bio has reported EBT for 8 years, with the latest figure at -$18.1 million in Q1 2026.
- Quarterly EBT fell 196.4% year-over-year to -$18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.3 million (down 33.56% YoY) and the FY2025 annual result came in at -$29.8 million, down 7.62% from the prior year.
- EBT retreated to -$18.1 million in Q1 2026 per ANVS's latest filing, from -$10.3 million in the prior quarter.
- Over five years, EBT peaked at -$1.1 million in Q1 2024 and troughed at -$22.2 million in Q4 2023.
- A 5-year average of -$9.2 million and a median of -$7.7 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT jumped 89.04% in 2024, then slumped 472.89% in 2025.
- Over 5 years, EBT stood at -$7.7 million in 2022, then tumbled by 187.51% to -$22.2 million in 2023, then soared by 64.38% to -$7.9 million in 2024, then tumbled by 30.38% to -$10.3 million in 2025, then tumbled by 75.63% to -$18.1 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$18.1 million, -$10.3 million, and -$7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | -14.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.12 Mn |
| Dec 31, 2025 | -10.32 Mn |
| Sep 30, 2025 | -7.53 Mn |
| Jun 30, 2025 | -6.35 Mn |
| Mar 31, 2025 | -6.11 Mn |
| Dec 31, 2024 | -7.91 Mn |
| Sep 30, 2024 | -12.64 Mn |
| Jun 30, 2024 | -5.02 Mn |
| Mar 31, 2024 | -1.07 Mn |
| Dec 31, 2023 | -22.21 Mn |
| Sep 30, 2023 | -14.72 Mn |
| Jun 30, 2023 | -9.54 Mn |
| Mar 31, 2023 | -9.74 Mn |
| Dec 31, 2022 | -7.73 Mn |
| Sep 30, 2022 | -6.43 Mn |
| Jun 30, 2022 | -5.94 Mn |
| Mar 31, 2022 | -5.23 Mn |
| Dec 31, 2021 | -5.91 Mn |
| Sep 30, 2021 | -2.85 Mn |
| Jun 30, 2021 | -2.52 Mn |